TRIM33 and cancer: Anti-transcriptional intermediary factor 1-gamma (anti-TIF1-γ) antibodies are specific markers of a subset of DM with a high risk of cancer, highlighting the importance of recognizing this paraneoplastic syndrome for early diagnosis and treatment.